-
公开(公告)号：US11142525B2
公开(公告)日：2021-10-12
申请号：US16679820
申请日：2019-11-11
Applicant: Pfizer Inc.
Inventor： Rebecca Anne Gallego , Sajiv Krishnan Nair , Robert Steven Kania , Omar Khaled Ahmad , Ted William Johnson , Jamison Bryce Tuttle , Mehran Jalaie , Michele Ann McTigue , Dahui Zhou , Matthew L. Del Bel , Ru Zhou , Mingying He , Anne-Marie Dechert Schmitt
IPC: C07D471/04 , A61P35/00
Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.
-
公开(公告)号：US20240197703A1
公开(公告)日：2024-06-20
申请号：US18144737
申请日：2023-05-08
Applicant: PFIZER INC.
Inventor： Joyann Barber , Sujin Cho-Schultz , Matthew L. Del Bel , Rebecca Anne Gallego , Mingying He , Mehran Jalaie , Robert Steven Kania , Michele Ann McTigue , Sajiv Krishnan Nair , Anne-Marie Dechert Schmitt , Jamison Bryce Tuttle , Dahui Zhou , Ru Zhou
IPC: A61K31/444 , A61K45/06 , C07D471/04 , C07D519/00
CPC classification number: A61K31/444 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: This invention relates to compounds of general Formula I
and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.-
公开(公告)号：US10220037B2
公开(公告)日：2019-03-05
申请号：US15612030
申请日：2017-06-02
Applicant: Pfizer Inc.
Inventor： John Howard Tatlock , Indrawan James McAlpine , Michelle Bich Tran-Dube , Eugene Yuanjin Rui , Martin James Wythes , Robert Arnold Kumpf , Michele Ann McTigue , Ryan Patman
IPC: C07D487/04 , A61K31/519 , C07D519/00 , A61K31/137 , A61K31/53 , C07D237/22 , C07D251/16 , C07D471/06 , C07D239/42 , C07D239/84 , C07D251/18 , C07D491/048 , A61P35/00 , A61P35/02 , A61P35/04 , A61K31/02 , C07C255/34
Abstract: Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
-
公开(公告)号：US08680111B2
公开(公告)日：2014-03-25
申请号：US13786106
申请日：2013-03-05
Applicant: Pfizer Inc.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: A01N43/42 , A61K31/44 , A01N43/02 , A61K31/335 , C07D471/00 , C07D491/00 , C07D498/00 , C07D513/00 , C07D515/00 , C07D313/00
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US20160244475A1
公开(公告)日：2016-08-25
申请号：US15045679
申请日：2016-02-17
Applicant: Pfizer Inc.
Inventor： John Howard Tatlock , Indrawan James McAlpine , Michelle Bich Tran-Dube , Eugene Yuanjin Rui , Martin James Wythes , Robert Arnold Kumpf , Michele Ann McTigue
CPC classification number: C07H19/14 , A61K31/7064 , C07H19/16 , C07H19/23 , C07H19/24
Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
Abstract translation: 通式（I）的化合物：这些化合物的制备方法，含有这些化合物的组合物，以及这些化合物的用途。
-
Patent Agency Ranking
公开(公告)号：US09133215B2
公开(公告)日：2015-09-15
申请号：US14156144
申请日：2014-01-15
Applicant: PFIZER INC.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/08 , C07D498/18 , C07D498/22 , C07D513/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US20130252961A1
公开(公告)日：2013-09-26
申请号：US13786106
申请日：2013-03-05
Applicant: PFIZER INC.
Inventor： Simon BAILEY , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D498/08 , C07D513/18 , C07D498/22 , C07D498/18 , C07D491/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Phi）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US11684616B2
公开(公告)日：2023-06-27
申请号：US17246551
申请日：2021-04-30
Applicant: PFIZER INC.
Inventor： Joyann Barber , Sujin Cho-Schultz , Matthew L. Del Bel , Rebecca Anne Gallego , Mingying He , Mehran Jalaie , Robert Steven Kania , Michele Ann McTigue , Sajiv Krishnan Nair , Anne-Marie Dechert Schmitt , Jamison Bryce Tuttle , Dahui Zhou , Ru Zhou
IPC: C07D471/04 , C07D519/00 , A61K31/444 , A61K45/06
CPC classification number: A61K31/444 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: This invention relates to compounds of general Formula I
and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.-
公开(公告)号：US20200172539A1
公开(公告)日：2020-06-04
申请号：US16679820
申请日：2019-11-11
Applicant: Pfizer Inc.
Inventor： Rebecca Anne Gallego , Sajiv Krishnan Nair , Robert Steven Kania , Omar Khaled Ahmad , Ted William Johnson , Jamison Bryce Tuttle , Mehran Jalaie , Michele Ann McTigue , Dahui Zhou , Matthew L. Del Bel , Ru Zhou , Mingying He
IPC: C07D471/04 , A61P35/00
Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.
-
公开(公告)号：US20170348313A1
公开(公告)日：2017-12-07
申请号：US15612030
申请日：2017-06-02
Applicant: Pfizer Inc.
Inventor： John Howard Tatlock , Indrawan James McAlpine , Michelle Bich Tran-Dube , Eugene Yuanjin Rui , Martin James Wythes , Robert Arnold Kumpf , Michele Ann McTigue , Ryan Patman
IPC: A61K31/519 , C07D471/06 , C07D251/16 , A61K31/137 , A61K31/53 , C07D519/00 , C07D237/22 , A61K31/02 , C07C255/34
CPC classification number: A61K31/519 , A61K31/02 , A61K31/137 , A61K31/53 , C07C255/34 , C07D237/22 , C07D239/42 , C07D239/84 , C07D251/16 , C07D251/18 , C07D471/06 , C07D487/04 , C07D491/048 , C07D519/00
Abstract: Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.037 seconds)
